Patents by Inventor Thayer White

Thayer White has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES
    Publication number: 20220089772
    Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Application
    Filed: September 29, 2021
    Publication date: March 24, 2022
    Applicant: GO Therapeutics, Inc.
    Inventor: Thayer WHITE
  • Anti-glyco-MUC1 antibodies and their uses
    Patent number: 11161911
    Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: November 2, 2021
    Assignee: GO Therapeutics, Inc.
    Inventor: Thayer White
  • ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES
    Publication number: 20210269552
    Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Application
    Filed: June 28, 2019
    Publication date: September 2, 2021
    Applicant: GO Therapeutics, Inc.
    Inventors: Thayer White, Hans H. WANDALL
  • ANTI-GLYCO-MUC1 ANTIBODIES AND THEIR USES
    Publication number: 20190119400
    Abstract: The present disclosure relates to anti-glyco-MUC1 antibodies and antigen binding fragments thereof that specifically bind to a cancer-specific glycosylation variant of MUC1 and related fusion proteins and antibody-drug conjugates, as well as nucleic acids encoding such biomolecules. The present disclosure further relates to use of the antibodies, antigen-binding fragments, fusion proteins, antibody-drug conjugates and nucleic acids for cancer therapy.
    Type: Application
    Filed: October 23, 2018
    Publication date: April 25, 2019
    Applicant: GO Therapeutics, Inc.
    Inventor: Thayer WHITE
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20070072856
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPAAT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Application
    Filed: November 16, 2006
    Publication date: March 29, 2007
    Applicant: Cell Therapeutics, Inc.
    Inventors: Baoqing Gong, John Tulinsky, Lynn Bonham, J. Klein, Robert Finney, David Hollenback, Scott Shaffer, Norina Tang, Thayer White, David Leung
  • LPAAT-beta inhibitors and uses thereof
    Publication number: 20060035896
    Abstract: The invention relates to triazines and the use thereof to inhibit lysophosphatidic acid acyltransferase ? (LPMT-?) activity. The invention further relates to methods of treating cancer using said triazines. The invention also relates to methods for screening for LPAAT-? activity.
    Type: Application
    Filed: September 12, 2005
    Publication date: February 16, 2006
    Applicant: Cell Therapeutics, Inc.
    Inventors: Lynn Bonham, J. Klein, Robert Finney, David Hollenback, Scott Shaffer, Norina Tang, Thayer White, David Leung, Baoqing Gong, John Tulinsky
  • Methods of separation and detection
    Patent number: 6331254
    Abstract: Methods which employ thin layer chromatography for separating and detecting hydrophobic target molecules are particularly useful in separating biologically relevant lipids. By utilizing non-destructive detection techniques, these methods also can be adapted to further quantification or structural analysis.
    Type: Grant
    Filed: December 17, 1999
    Date of Patent: December 18, 2001
    Assignee: Cell Therapeutics, Inc.
    Inventors: Thayer White, Edward Nudelman
  • ABO genotyping
    Patent number: 5326857
    Abstract: The genes defining the ABO histo-blood groups are disclosed. Methods for identification of histo-blood group ABO status are provided. The methods include the use of DNA probes or size separation of DNA fragments unique to a blood group status. The present invention also discloses DNA constructs, recombinant methods for providing histo-blood glycosyltransferases, methods for tumor suppression, purified histo-blood group glycosyltransferases, and antibodies produced therefrom which bind to protein epitopes.
    Type: Grant
    Filed: August 29, 1991
    Date of Patent: July 5, 1994
    Assignee: The Biomembrane Institute
    Inventors: Fumi-ichiro Yamamoto, Thayer White, Sen-itiroh Hakomori, Henrik Clausen
  • Purified histo-blood group A glycosyltransferase and antibodies thereto
    Patent number: 5068191
    Abstract: The genes defining the ABO histo-blood groups are disclosed. Methods for identification of histo-blood group ABO status are provided. The methods include the use of DNA probes or size separation of DNA fragments unique to a blood group status. The present invention also discloses DNA constructs, recombinant methods for providing histo-blood glycosyltransferases, methods for tumor suppression, purified histo-blood group glycosyltransferases, and antibodies produced therefrom which bind to protein epitopes.
    Type: Grant
    Filed: August 31, 1989
    Date of Patent: November 26, 1991
    Assignee: The Biomembrane Institute
    Inventors: Henrik Clausen, Fumi-ichiro Yamamoto, Thayer White, Sen-itiroh Hakomori